We are live on
!
Find out more
AG
Aperio Group Portfolio holdings
AUM
$33.8B
1-Year Est. Return
31.46%
This Fund
S&P 500
This Quarter
Est. Return
+9.4%
1 Year Est. Return
+31.46%
3 Year Est. Return
+70.41%
5 Year Est. Return
+146.02%
10 Year Est. Return
–
AUM
$27.8B
AUM Growth
+$2.54B
(+10%)
Cap. Flow
+$477M
Cap. Flow
% of AUM
1.71%
Top 10 Holdings %
Top 10 Hldgs %
17.19%
Holding
2,397
New
92
Increased
1,264
Reduced
960
Closed
73
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$37.3M |
| 2 |
Johnson & Johnson
JNJ
|
+$35.5M |
| 3 |
Verizon
VZ
|
+$26.4M |
| 4 |
Truist Financial
TFC
|
+$26.1M |
| 5 |
CTXS
Citrix Systems Inc
CTXS
|
+$18.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$53.1M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$25.3M |
| 3 |
CHL
China Mobile Limited
CHL
|
+$16.9M |
| 4 |
CUK
Carnival PLC
CUK
|
+$15M |
| 5 |
WBK
Westpac Banking Corporation
WBK
|
+$14.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.1% |
| 2 | Financials | 16.78% |
| 3 | Healthcare | 13.34% |
| 4 | Consumer Discretionary | 9.48% |
| 5 | Communication Services | 8.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
Garrett Motion
GTX
$5.78B
| $269K | ﹤0.01% |
26,954
-5,341
| -17% | -$54.5K |
|
|
ISBC
2102
DELISTED
Investors Bancorp, Inc.
ISBC
| $269K | ﹤0.01% |
22,592
+895
| +4% | +$10.7K |
|
2103
Perdoceo Education
PRDO
$2.04B
| $268K | ﹤0.01% |
14,557
-3,003
| -17% | -$48.9K |
|
2104
Huron Consulting
HURN
$2.61B
| $266K | ﹤0.01% |
3,868
-185
| -5% | -$12K |
|
2105
Talos Energy
TALO
$2.44B
| $266K | ﹤0.01% |
+8,813
| New | +$206K |
|
2106
Central Garden & Pet Co
CENT
$2.71B
| $264K | ﹤0.01% |
+10,615
| New | +$253K |
|
2107
Cannae Holdings
CNNE
$646M
| $262K | ﹤0.01% |
+7,038
| New | +$231K |
|
2108
Regenxbio
RGNX
$648M
| $262K | ﹤0.01% |
+6,397
| New | +$253K |
|
2109
Standard Motor Products
SMP
$861M
| $262K | ﹤0.01% |
4,922
+24
| +0.5% | +$1.23K |
|
2110
Argan
AGX
$8.13B
| $261K | ﹤0.01% |
6,498
-121
| -2% | -$4.65K |
|
|
GNFT
2111
DELISTED
Genfit
GNFT
| $260K | ﹤0.01% |
+13,090
| New | +$205K |
|
2112
1-800-Flowers.com
FLWS
$246M
| $259K | ﹤0.01% |
17,863
-641
| -3% | -$8.71K |
|
2113
AnaptysBio
ANAB
$1.63B
| $258K | ﹤0.01% |
+15,849
| New | +$375K |
|
2114
Moelis & Co
MC
$5.08B
| $256K | ﹤0.01% |
8,013
-272
| -3% | -$8.9K |
|
|
DOOR
2115
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $256K | ﹤0.01% |
+3,546
| New | +$233K |
|
2116
BancFirst
BANF
$3.77B
| $255K | ﹤0.01% |
4,077
-150
| -4% | -$8.83K |
|
2117
AngioDynamics
ANGO
$610M
| $254K | ﹤0.01% |
15,886
+4,887
| +44% | +$74.6K |
|
|
SHOE
2118
Shoe Station Group
SHOE
$420M
| $253K | ﹤0.01% |
13,588
| – | – |
|
2119
Corcept Therapeutics
CORT
$12.7B
| $251K | ﹤0.01% |
20,782
-1,984
| -9% | -$27.6K |
|
2120
Griffon
GFF
$4.03B
| $251K | ﹤0.01% |
12,355
+519
| +4% | +$10.9K |
|
2121
First Bancorp
FBNC
$2.61B
| $250K | ﹤0.01% |
+6,264
| New | +$240K |
|
2122
Liberty Latin America Class A
LILA
$1.63B
| $250K | ﹤0.01% |
20,211
+457
| +2% | +$5.31K |
|
2123
Gorman-Rupp
GRC
$2.13B
| $249K | ﹤0.01% |
6,633
-90
| -1% | -$3.28K |
|
2124
Helios Technologies
HLIO
$2.57B
| $249K | ﹤0.01% |
5,388
-376
| -7% | -$16.1K |
|
|
GWPH
2125
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $249K | ﹤0.01% |
2,386
-1,395
| -37% | -$156K |
|
Similar funds
OU
CTA
GAM
CCI
SWM
LCM
HCMNY
BII
Aperio Group's Q4 2019 Portfolio in Review
As of Q4 2019, Aperio Group held 2,397 positions worth $27.8B, up 10% from $25.3B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Aperio Group's Q4 2019 filing shows 92 new, 1,264 increased, 960 reduced and 73 closed positions. Its largest new stake was Cerence: 67,887 shares worth $1.54M. The largest sale was Celgene Corp, an estimated $53.1M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- Aperio Group's largest Q4 2019 buy was Cerence: 67,887 shares worth $1.54M.
- Aperio Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $37.3M increase.
- Aperio Group's biggest Q4 2019 reduction was China Mobile Limited, cutting an estimated $16.9M.
- Aperio Group fully exited Celgene Corp in Q4 2019, selling an estimated $53.1M.
- Aperio Group's ten largest holdings make up 17% of its $27.8B portfolio in Q4 2019.
- Aperio Group opened 92 new positions and closed 73 in Q4 2019.
- Aperio Group's portfolio value rose 10% quarter-over-quarter to $27.8B.
Based on Aperio Group's 13F filing for Q4 2019, filed 13 Feb 2020.